Vitamin D needs K2 to work safely

Taking vitamin D with K2 rests on a real biological pathway, and two placebo-controlled trials published in 2026 found that K2 slowed the build-up of calcium in heart arteries. What they show is narrower than what the label on the bottle implies: both measured a calcium score rather than heart attacks, and the one that paired K2 with vitamin D studied people with severe existing calcification.

Four trials tested parts of the idea that vitamin D is unsafe without K2, and none found the harm it predicts. Seven years of 400 IU of vitamin D with calcium and no K2 did not raise artery calcium scores compared with placebo, vitamin D did not lower vitamin K status in a 12 month trial in girls or an eight week trial in adults, and adding K2 to vitamin D for three years made no difference to bone density. Small Japanese trials that gave prescription doses of both vitamins did find a small gain in spine bone density with the pair, at about 45 milligrams of K2 a day, hundreds of times a typical capsule. None of this speaks to high doses of vitamin D, which carry a documented risk of their own, described below.

The idea is that vitamin D increases calcium absorption, and vitamin K is what directs calcium into bone and keeps it out of artery walls. If D raises calcium while K is short, the worry is that calcium ends up in the wrong place. Each step of that pathway is real and measurable; how the steps add up in a living artery is less fully mapped. The specific premise that vitamin D depletes vitamin K was tested directly. A 12 month trial gave vitamin D3 to girls aged 11 and 12 and measured undercarboxylated osteocalcin, the standard marker of vitamin K status, and it did not move. The trial found no sign that vitamin D lowers vitamin K status. A 2026 analysis of an eight week trial in about 170 adults with high blood pressure, given 2,800 IU of vitamin D3 a day or placebo, also found no change in blood levels of vitamin K1 or of K2 as MK-7. That analysis was planned after the trial ended, and the trial was short.

The strongest evidence for the pair is a 2026 trial in 398 people with severe existing coronary calcification, all with calcium scores at or above 400. Over two years, calcium scores rose 196 points on K2 and D3 versus 248 on placebo. It was double blind, placebo controlled, registered before enrolment began, and it met the outcome it set out to measure. It also used K2 as MK-7 at 720 micrograms, which is the same form sold in supplements, though roughly four to eight times the dose in a typical capsule. A second 2026 trial, from the Netherlands, tested K2 on its own in 180 people with symptomatic coronary artery disease and lower calcium scores, between 50 and 400. Over two years, median scores rose from 145 to 214 on placebo and from 135 to 184 on 360 micrograms of MK-7 a day, a difference the authors report as significant. It carries the effect below severe calcification and to a lower dose, still two to four times a typical capsule. It gave no vitamin D, so it speaks to what K2 does in arteries rather than to whether vitamin D needs it.

Three things sit alongside these results. The outcome in both trials was a calcium score, not a heart attack or a stroke: slowing a number on a scan is not the same as preventing an event, and neither trial tested whether it does. The people studied already had coronary disease or calcification, which is not the person adding K2 to a daily vitamin D capsule. And vitamin K2 manufacturers were involved in both: the Danish trial protocol lists one among its funders alongside a public research foundation and a university hospital, and in the Dutch trial a manufacturer supplied the tablets while a heart foundation grant funded the work. The Danish research group ran an earlier trial in 304 people and found nothing overall. Calcium progression did not differ significantly between groups. An effect showed up only in the subgroup who already had calcium scores above 400, which the authors described as a starting point for further work rather than a finding. The 2026 trial was then built around exactly that subgroup and confirmed it. On its own the earlier trial reads as null and the later one as positive; the second was designed around the first one's subgroup.

On bone, a 2020 pooling of eight trials and 971 people found vitamin K with vitamin D raised bone density slightly, but against no treatment rather than against vitamin D alone. A 2020 network analysis of 90 trials did make the comparison against vitamin D alone and found the pair slightly ahead at the spine, by 0.023 grams per square centimetre. That result rests on three small Japanese trials that gave 45 milligrams of K2 a day, a prescription dose for osteoporosis in Japan, with a prescription form of activated vitamin D, so it describes a drug regimen rather than a supplement. In the same analysis, adding vitamin K when calcium and vitamin D were given to both groups made no difference at the spine, and no hip result was reported for the pair. A three year trial that made the comparison at a supplement dose, in 142 women with low bone density who all took vitamin D and calcium, found bone density fell by similar amounts whether or not they also took 375 micrograms of K2, even though the K2 was clearly absorbed and active. A supplement company part-funded that trial and supplied its tablets. Across vitamin K trials on arteries more broadly, the most recent pooling, 14 trials and 1,533 people up to 2022, found a small slowing of coronary calcium scores, but that result came from four trials with 424 people, and six of the eight trials reporting other calcification measures found no difference. A trial in generally healthy adults using vitamin K1 rather than K2 found no meaningful difference in artery calcium over three years. A trial in kidney disease found no improvement in arterial stiffness.

On safety, vitamin K interferes with warfarin and other vitamin K antagonist blood thinners. Adding K2 changes vitamin K intake, which is what these drugs are dosed against. The US prescribing label for warfarin, sold as Jantoven, describes warfarin as a vitamin K antagonist, states that the amount of vitamin K in food may affect therapy, and advises patients to keep a consistent amount of vitamin K in their diet and to tell their healthcare providers about all vitamins and supplements they take. Vitamin D has a documented harm of its own at high intakes, which is too much calcium in the blood. LiverTox, the US government's drug-induced liver injury database, reports that vitamin D intoxication generally arises with intakes above 50,000 IU a day, and that lower doses can cause it in susceptible people such as those with renal osteodystrophy, a bone disorder of kidney disease. It lists symptoms including thirst, nausea, vomiting, constipation, fatigue, bone pain and muscle cramps, with possible kidney damage, and names mislabeled supplements, over-fortified milk or foods, and prescription or dispensing errors as common causes. It rates vitamin D an unlikely cause of liver injury. For children, the nutrition committee of the Austrian paediatric society reviewed the research in 2020, found no randomized trial of the pair in children and no studies to set a K2 dose, and concluded that giving the two together in childhood is not justified and cannot be recommended.